CR11504A - Deteccion mejorada de la expresion de mage-a - Google Patents

Deteccion mejorada de la expresion de mage-a

Info

Publication number
CR11504A
CR11504A CR11504A CR11504A CR11504A CR 11504 A CR11504 A CR 11504A CR 11504 A CR11504 A CR 11504A CR 11504 A CR11504 A CR 11504A CR 11504 A CR11504 A CR 11504A
Authority
CR
Costa Rica
Prior art keywords
mage
expression
improved detection
detection
improved
Prior art date
Application number
CR11504A
Other languages
English (en)
Inventor
Katja Bierau
Ilse Vlassenbroeck
Original Assignee
Oncomethylome Sciences Sa
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomethylome Sciences Sa, Glaxosmithkline Biolog Sa filed Critical Oncomethylome Sciences Sa
Publication of CR11504A publication Critical patent/CR11504A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/30—Oligonucleotides characterised by their secondary structure
    • C12Q2525/301—Hairpin oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/113—Real time assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/10—Detection mode being characterised by the assay principle
    • C12Q2565/101—Interaction between at least two labels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un aligonucleótido, cebador o sonda comprende la secuencia de nucleotidos de cualquiera de las SEQ ID NOs: 5, 6, 7, 2, 3, 4, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 ó 25.
CR11504A 2007-09-17 2010-06-16 Deteccion mejorada de la expresion de mage-a CR11504A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96012807P 2007-09-17 2007-09-17

Publications (1)

Publication Number Publication Date
CR11504A true CR11504A (es) 2011-05-10

Family

ID=40239643

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11504A CR11504A (es) 2007-09-17 2010-06-16 Deteccion mejorada de la expresion de mage-a

Country Status (18)

Country Link
US (4) US9050280B2 (es)
EP (2) EP2198045A1 (es)
JP (1) JP5406839B2 (es)
KR (1) KR20100085917A (es)
CN (1) CN101932723B (es)
AU (1) AU2008300397A1 (es)
BR (1) BRPI0817008A2 (es)
CA (2) CA2699856C (es)
CO (1) CO6260156A2 (es)
CR (1) CR11504A (es)
DO (1) DOP2010000076A (es)
EA (1) EA017879B1 (es)
IL (1) IL204525A0 (es)
MA (1) MA31753B1 (es)
MX (1) MX2010002965A (es)
NZ (2) NZ583796A (es)
WO (2) WO2009037438A1 (es)
ZA (1) ZA201001878B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012037128A2 (en) * 2010-09-14 2012-03-22 The University Of North Carolina At Chapel Hill Methods and kits for detecting melanoma
WO2012129488A2 (en) * 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
CA2897474A1 (en) 2013-01-24 2014-07-31 California Institute Of Technology Chromophore-based characterization and detection methods
EP2971179B1 (en) 2013-03-14 2019-01-09 Mayo Foundation for Medical Education and Research Detecting neoplasm
GB2550712B (en) 2015-02-26 2021-01-13 Hitachi High Tech Corp Method for constructing hairpin-containing nucleic acid molecules for nanopore sequencing
CN105100961B (zh) * 2015-07-23 2018-03-13 华为技术有限公司 视频缩略图生成方法及生成装置
DE102016005947B3 (de) 2016-05-16 2017-06-08 Dimo Dietrich Verfahren zur Abschätzung der Prognose und zur Prädiktion des Ansprechens auf eine Immuntherapie von Patienten mit malignen Erkrankungen
US11685955B2 (en) 2016-05-16 2023-06-27 Dimo Dietrich Method for predicting response of patients with malignant diseases to immunotherapy
US10294518B2 (en) 2016-09-16 2019-05-21 Fluxion Biosciences, Inc. Methods and systems for ultra-sensitive detection of genomic alterations
EP3596236B1 (en) 2017-03-17 2021-06-02 MDxHealth SA Mgmt epigenetic deep-sequencing assay
US20180271710A1 (en) * 2017-03-22 2018-09-27 Bragi GmbH Wireless earpiece for tinnitus therapy
EP3655418A4 (en) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. METHOD OF TREATMENT OF GLIOBLASTOMA
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF
US11441182B2 (en) * 2018-08-08 2022-09-13 Virginia Commonwealth University Multiplexed and recyclable single-molecule sensors for quantitative analysis of nucleic-acid biomarkers
CN109540856B (zh) * 2018-11-08 2022-01-28 南京师范大学 一种基于荧光共振能量转移检测不同亚型乳腺癌细胞的试剂
CN111551978B (zh) * 2020-05-08 2022-09-27 中国辐射防护研究院 一种放射性土壤样品采样过程不确定度的评定方法
WO2023108145A1 (en) * 2021-12-10 2023-06-15 Nuprobe Usa, Inc. Universal probes for amplification and detection of nucleic acids
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
IE72468B1 (en) 1987-07-31 1997-04-09 Univ Leland Stanford Junior Selective amplification of target polynucleotide sequences
ZA899593B (en) 1988-12-16 1990-09-26 Siska Diagnostics Inc Self-sustained,sequence replication system
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ES2108278T3 (es) 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6117635A (en) * 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
SI1659178T1 (sl) 1998-02-05 2010-07-30 Glaxosmithkline Biolog Sa Postopek za čiščenje ali proizvodnjo MAGE proteina
US6768000B1 (en) * 1998-06-12 2004-07-27 Intergen Company Multi-fluorescent hairpin energy transfer oligonucleotides
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
US6667037B1 (en) * 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6331393B1 (en) * 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US20040170977A1 (en) * 2000-03-31 2004-09-02 Peter Laird Epigenetic sequences for esophageal adenocarcinoma
JP2004531251A (ja) 2001-03-15 2004-10-14 シュレンツェル，ジャック メチシリン耐性黄色ブドウ球菌（ｍｒｓａ）の直接検出の方法
AU2002360429A1 (en) 2001-11-26 2003-06-10 Avigen, Inc. Methods for producing stocks of recombinant aav virions
KR100885008B1 (ko) 2002-02-04 2009-02-20 코릭사 코포레이션 신규 면역효과기 화합물
DE10215770A1 (de) * 2002-04-10 2003-10-30 Michael Giesing Verfahren zum Nachweis methylierter und/oder nichtmethylierter Cytosine in Nukleinsäuren, dessen Verwendung sowie entsprechende Analysekits
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
WO2004087957A2 (en) 2003-04-03 2004-10-14 Oncomethylome Sciences S.A. Hypermethylated genes and cervical cancer
US7881873B2 (en) * 2003-04-29 2011-02-01 The Jackson Laboratory Systems and methods for statistical genomic DNA based analysis and evaluation
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
DE10338308B4 (de) * 2003-08-15 2006-10-19 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierungen in DNA
WO2005042713A2 (en) 2003-10-28 2005-05-12 The Johns Hopkins University Quantitative multiplex methylation-specific pcr
US20050130170A1 (en) * 2003-12-16 2005-06-16 Jeanne Harvey Identification and verification of methylation marker sequences
US7700282B2 (en) * 2004-10-11 2010-04-20 Epigenomics Ag Method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids
US20070059753A1 (en) * 2005-09-15 2007-03-15 Tatiana Vener Detecting gene methylation
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB0700374D0 (en) * 2007-01-09 2007-02-14 Oncomethylome Sciences S A NDRG family methylation markers
US8911937B2 (en) * 2007-07-19 2014-12-16 Brainreader Aps Method for detecting methylation status by using methylation-independent primers

Also Published As

Publication number Publication date
WO2009037438A1 (en) 2009-03-26
CA2699856C (en) 2019-08-20
CN101932723B (zh) 2014-09-10
BRPI0817008A2 (pt) 2017-05-16
US20110287416A1 (en) 2011-11-24
DOP2010000076A (es) 2010-08-15
CA2699853A1 (en) 2009-03-26
US9050280B2 (en) 2015-06-09
WO2009037438A8 (en) 2010-04-15
NZ583796A (en) 2011-12-22
EP2201131B8 (en) 2014-12-10
US8481700B2 (en) 2013-07-09
US10053724B2 (en) 2018-08-21
EA017879B1 (ru) 2013-03-29
IL204525A0 (en) 2010-11-30
EP2201131A1 (en) 2010-06-30
KR20100085917A (ko) 2010-07-29
MX2010002965A (es) 2010-09-14
JP5406839B2 (ja) 2014-02-05
JP2010538633A (ja) 2010-12-16
MA31753B1 (fr) 2010-10-01
US20130302363A1 (en) 2013-11-14
CA2699856A1 (en) 2009-03-26
WO2009037441A1 (en) 2009-03-26
NZ596545A (en) 2013-05-31
ZA201001878B (en) 2011-05-25
EA201000334A1 (ru) 2011-02-28
AU2008300397A1 (en) 2009-03-26
EP2201131B1 (en) 2014-11-05
US20160032368A1 (en) 2016-02-04
US20100280105A1 (en) 2010-11-04
CO6260156A2 (es) 2011-03-22
CN101932723A (zh) 2010-12-29
EP2198045A1 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
CR11504A (es) Deteccion mejorada de la expresion de mage-a
CY1119706T1 (el) Διεργασια για την παρασκευη ενωσεων χρησιμων ως αναστολεων toy sglt
GT201200189A (es) Antagonistas de pcsk9
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
TW200622950A (en) Methods of monitoring the concentration of an analyte
EA200701918A1 (ru) Белок липокалин
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
DE602006015793D1 (de) Proteolipidmembran und lipidmembranen-biosensor
CR20110357A (es) Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h- benzo-(c) (1,2)-oxaborol-1-ol
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2011047087A3 (en) Protein detection via nanoreporters
MX2007010349A (es) Composiciones y metodos para clasificar muestras biologicas.
EA201000327A1 (ru) Белок
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EA200702643A1 (ru) Антитела, связывающие tweak
CY1120055T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1114023T1 (el) Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
CL2007002388A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.
RS54451B1 (en) TOLL-LIKE RECEPTOR ANTAGONISTS 3
MX2007010332A (es) Metodos y composiciones para promover adhesion o migracion de celula endotelial.
WO2009007649A3 (fr) Dispositif et procede d'identification et de determination de groupes sanguins
ATE447628T1 (de) Einzelsequenzhybridisierungssonden
ATE549351T1 (de) Chimärer peptidantagonist für gpcr135 oder gpcr142
FR2902101B1 (fr) Peptides a activite anti-proliferative

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)